2023
SYSTEMIC DELIVERY, LOCAL ACTIVITY

Press Release

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”

In the news

GeekWire

Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies

Media

Genetic Engineering & Biotechnology News

From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines

Media

Endpoints News

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs

Media

Biocentury

Sequel company Bonum emerges in wake of Roche’s Good Tx acquisition

Media

BioWorld

Bonum to continue Good work after $250M cash acquisition deal with Roche

Media

Endpoints News

Good Therapeutics sells PD-1 IL-2 program to Roche for $250M and will march on with a similar name, but in Latin

Media

Also seen in

In Vivo Pharma Intelligence

The Busiest Dealmakers Of 2022

Media

Puget Sound Business Journal

Seattle biotech Bonum raises $93M Series A round

Media

The pharmaletter

Good Therapeutics spinout Bonum banks $93 million in Series A

Media

BioSpace

Good Therapeutics’ Offshoot Bonum Launches with $93 Million in Series A (Updated)

Media

FierceBiotech

Roche-backed Bonum bags $93M series A to develop new class of conditionally active therapies

Media

Wall Street Journal

Healthcare Investor Digitalis Ventures Nets $300 Million Fund

Media

Biopharmadive

Roche to pay $250M for Good Therapeutics and its targeted drug technology

Media

Scrip

Roche Buys IL-2 Technology From Good, Which Forms New Firm Bonum

Media

Blog

6 Tips For Successful Drug Discovery Teamwork

Blog

The View from Business Development at Bonum Therapeutics

Blog

Welcome to Bonum Therapeutics

Blog